Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$10.1 - $11.6 $3,625 - $4,164
359 Added 50.92%
1,064 $11,000
Q1 2023

May 08, 2023

BUY
$10.37 - $12.56 $124 - $150
12 Added 1.73%
705 $7,000
Q4 2022

Feb 13, 2023

SELL
$9.9 - $12.43 $12,612 - $15,835
-1,274 Reduced 64.77%
693 $8,000
Q3 2022

Nov 14, 2022

SELL
$10.14 - $12.38 $12,157 - $14,843
-1,199 Reduced 37.87%
1,967 $20,000
Q2 2022

Aug 15, 2022

SELL
$11.05 - $12.72 $1.4 Million - $1.62 Million
-127,084 Reduced 97.57%
3,166 $37,000
Q1 2022

May 13, 2022

SELL
$10.61 - $12.88 $3.93 Million - $4.77 Million
-370,569 Reduced 73.99%
130,250 $1.64 Million
Q4 2021

Feb 14, 2022

BUY
$10.86 - $13.95 $6,722 - $8,635
619 Added 0.12%
500,819 $5.84 Million
Q3 2021

Nov 15, 2021

BUY
$11.92 - $13.92 $231,546 - $270,396
19,425 Added 4.04%
500,200 $6.53 Million
Q2 2021

Aug 16, 2021

SELL
$10.16 - $13.11 $67,188 - $86,696
-6,613 Reduced 1.36%
480,775 $6.19 Million
Q1 2021

May 13, 2021

SELL
$9.04 - $11.86 $138,845 - $182,157
-15,359 Reduced 3.06%
487,388 $5.45 Million
Q4 2020

Feb 12, 2021

BUY
$9.05 - $12.2 $12,724 - $17,153
1,406 Added 0.28%
502,747 $5.73 Million
Q3 2020

Nov 12, 2020

SELL
$8.99 - $10.74 $785,510 - $938,418
-87,376 Reduced 14.84%
501,341 $4.51 Million
Q2 2020

Aug 13, 2020

BUY
$9.14 - $11.97 $59,839 - $78,367
6,547 Added 1.12%
588,717 $6.08 Million
Q1 2020

May 13, 2020

BUY
$8.58 - $14.01 $656,241 - $1.07 Million
76,485 Added 15.13%
582,170 $5.87 Million
Q4 2019

Feb 14, 2020

BUY
$8.22 - $14.0 $3.24 Million - $5.52 Million
394,375 Added 354.3%
505,685 $6.73 Million
Q3 2018

Nov 13, 2018

BUY
$14.31 - $17.65 $1.59 Million - $1.96 Million
111,310 New
111,310 $2.06 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $530M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.